Does ADMA inhibit eNOS and reduce nitric oxide availability?

ADMA (asymmetric dimethylarginine) is an endogenous inhibitor of nitric-oxide synthase with a biologically coherent role in impaired endothelial signaling. The full pathway in the claim is supported by biochemical, cellular, and human vascular evidence.

Clinical and vascular evidence

• ADMA competitively inhibits eNOS at the L-arginine substrate-binding site. Reported inhibitory constants vary by assay (Ki approximately 0.9–4.8 µM; one recombinant-system IC50 about 12 µM), as expected for substrate-dependent competitive inhibition.
• In endothelial cells, 5 and 10 µM ADMA reduced NO-related output by roughly 46% and 58%, respectively; excess L-arginine substantially attenuated inhibition at 5 µM.
• Higher ADMA is inversely associated with brachial flow-mediated dilation (FMD), and intra-arterial ADMA administration reduces forearm vasodilator responses—evidence that impaired NO signaling translates into reduced endothelium-dependent vasodilation.
• FMD is clinically meaningful: across 23 prospective studies, each 1% higher FMD was associated with 8% lower subsequent cardiovascular-disease risk. Elevated ADMA also predicted incident cardiovascular disease (highest versus lowest tertile: RR 1.42, 95% CI 1.29–1.56).

Mechanistic context

• eNOS inhibition lowers endothelial NO synthesis; ADMA’s effect depends on intracellular exposure and the L-arginine/ADMA balance. Typical plasma ADMA (~0.4–0.5 µM) is below many experimental inhibitory concentrations, so plasma concentration alone does not quantify intracellular vascular effect.
• Oxidative stress and tetrahydrobiopterin (BH₄) depletion may promote eNOS uncoupling, shifting output from NO toward superoxide. Superoxide consumes NO to form peroxynitrite, reinforcing NO deficiency. Controlled ADMA infusion also dose-dependently increases systemic vascular resistance.

Bottom line

• The claim is strongly supported: ADMA can inhibit eNOS, reduce NO bioavailability, and contribute to endothelial dysfunction, with oxidative eNOS uncoupling providing a plausible amplifying mechanism in vascular disease.